Medicine and Dentistry
Parathyroidectomy
100%
End Stage Renal Disease
73%
Secondary Hyperparathyroidism
68%
Hyperparathyroidism
66%
Parathyroid Hormone
50%
Tertiary Hyperparathyroidism
48%
Hyperthermic Intraperitoneal Chemotherapy
44%
Cytoreductive Surgery
41%
Kidney Transplantation
39%
Calcimimetic
37%
Peritoneum Metastasis
33%
Isotopes of Calcium
31%
Severe Acute Respiratory Syndrome Coronavirus 2
29%
Cinacalcet
28%
Retrospective Study
25%
Diagnosis
23%
Surgery
22%
Hormone Determination
20%
Quality of Life
20%
Cancer Surgery
19%
Infection
19%
Abdominal Cancer
19%
Liver Transplantation
19%
Surgeon
15%
Kidney Function
14%
Graft Failure
14%
Overall Survival
13%
Cohort Analysis
12%
Cohort Study
12%
Parathyroid
12%
Transplantation
11%
Protein Intake
11%
Caloric Intake
11%
Peritoneum Cancer
11%
Laparoscopy
10%
Vitamin D
10%
Hyperphosphatemia
10%
Postoperative Complication
10%
Primary Hyperparathyroidism
9%
Systematic Review
9%
Symptomatic Treatment
9%
Physical Activity
9%
Anticoagulation
9%
Autograft
9%
Right Hepatic Artery
9%
Flushing
9%
Clinical Study
9%
Thromboembolism
9%
Malignant Neoplasm
9%
Observational Study
9%
Keyphrases
Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
45%
Parathyroidectomy
34%
Colorectal Peritoneal Metastases
32%
Kidney Transplantation
26%
End-stage Renal Disease
21%
Hyperparathyroidism
20%
Abdominal Cancer Surgery
19%
Narrative Review
19%
Cinacalcet
19%
Tertiary Hyperparathyroidism
14%
Prognostic Factors
12%
Total Parathyroidectomy
11%
Peritoneal Cancer Index
11%
Retrospective Analysis
10%
Diagnostic Laparoscopy
10%
Surgeons
10%
Serum Calcium
9%
Adenosine Triphosphate
9%
Secondary and Tertiary Hyperparathyroidism
9%
Graft Outcome
9%
Treatment Options
9%
Retrospective Observational Study
9%
Extent of Surgery
9%
Secondary Hyperparathyroidism
9%
Plasma Phosphate
9%
Survival Outcomes
9%
Physical Activity
9%
Intraperitoneal Chemotherapy
9%
Donor Liver
9%
Death-censored Graft Survival
9%
PTH Level
9%
Primary Hyperparathyroidism (pHPT)
9%
Patient Outcomes
9%
Diagnostic Approach
9%
Fluorescence-guided Surgery
9%
Peritoneal Carcinomatosis
9%
Plasma Calcium
9%
Diagnostic Interventions
9%
Accessory Right Hepatic Artery
9%
COVIDSurg
9%
Metachronous
9%
Sars-cov-2 Infection
9%
Renal Function
9%
End-stage Renal Disease Patients
8%
Disease-related
7%
Static Cold Storage
6%
Recipient Age
6%
Generalized Estimating Equations
6%
Graft Function
6%
Overall Survival
6%
Pharmacology, Toxicology and Pharmaceutical Science
End Stage Renal Disease
45%
Hyperparathyroidism
39%
Parathyroid Hormone
37%
Cinacalcet
32%
Secondary Hyperparathyroidism
30%
Tertiary Hyperparathyroidism
29%
Intraperitoneal Chemotherapy
16%
Retrospective Study
12%
Peritoneum Metastasis
11%
Portal Vein Thrombosis
9%
Clinical Study
9%
SARS Coronavirus
9%
Infection
9%
Thromboembolism
9%
Peritoneum Cancer
9%
Abdominal Cancer
9%
Primary Hyperparathyroidism
9%
Overall Survival
9%
Recurrent Disease
8%
Vitamin D
7%
Graft Failure
7%
Hyperphosphatemia
6%
Combination Therapy
6%
